Sumitomo Dainippon


Concise Prescribing Info
Meropenem trihydrate
Lower resp tract, intra-abdominal, gynaecological (including postpartum), skin & skin structure infections; UTI (including complicated); septicaemia; meningitis. Empiric treatment including initial monotherapy for presumed bacterial infections in host-compromised neutropenic patients. Polymicrobial infections. As monotherapy or in combination w/ other antibacterial agents in patients w/ cystic fibrosis & chronic lower resp tract infections.
Dosage/Direction for Use
IV bolus inj over 5 min or IV infusion over 15-30 min. Adult Dose range: 1.5-6 g daily in 3 divided doses. Usual dose: 500 mg-1 g IV every 8 hr. Childn >50 kg Adult dose. Infant & childn >3 mth & up to 12 yr 10-40 mg/kg IV every 8 hr. Febrile episodes in neutropenic patients Adult 1 g every 8 hr. Childn 20 mg/kg every 8 hr. Meningitis/cystic fibrosis Adult g every 8 hr. Childn 40 mg/kg every 8 hr. Infections caused by Pseudomonas aeruginosa Adult At least 1 g every 8 hr. Max: 6 g daily in 3 divided doses. Childn At least 20 mg/kg every 8 hr. Max: 120 mg/kg daily in 3 divided doses. Renal impairment CrCl 26-50 mL/min 1 u dose every 12 hr, 10-25 mL/min ½ u dose every 12 hr, <10 mL/min ½ u dose every 24 hr.
Special Precautions
History of hypersensitivity to carbapenems, penicillins or other β-lactam antibiotics. W/draw immediately & consider alternative treatment if signs & symptoms of severe cutaneous adverse reactions (eg, Steven-Johnson syndrome, toxic epidermal necrolysis, drug reaction w/ eosinophilia and systemic symptoms, erythema multiforme, acute generalised exanthematous pustulosis) appears. Overgrowth of non-susceptible organism may occur. Consider diagnosis of pseudomembranous colitis in patients who develop diarrhea. Monitor liver function in patients w/ preexisting liver disorders. Concomitant use w/ valproic acid/sodium valproate is not recommended. +ve direct/indirect Coombs' test. Renal insufficiency. May affect ability to drive or operate machinery. Pregnancy & lactation. Not recommend in infant <3 mth.
Adverse Reactions
Thrombocythaemia; headache; diarrhoea, vomiting, nausea; increased ALT/AST, blood alkaline phosphatase, blood lactate dehydrogenase, γ-glutamyltransferase; rash, pruritus; inflammation, pain.
Drug Interactions
Increased elimination t1/2 & plasma conc w/ probenecid. Decreased blood levels of valproic acid.
MIMS Class
Other Beta-Lactams
ATC Classification
J01DH02 - meropenem ; Belongs to the class of carbapenems. Used in the systemic treatment of infections.
Meronem inj 1 g
1's (P3,846/vial)
Meronem inj 500 mg
1's (P2,301/vial)
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in